Enzymotec Ltd Company Profile (NASDAQ:ENZY)

About Enzymotec Ltd (NASDAQ:ENZY)

Enzymotec Ltd logoEnzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ENZY
  • CUSIP: N/A
  • Web: www.enzymotec.com
Capitalization:
  • Market Cap: $184.7 million
  • Outstanding Shares: 22,944,000
Average Prices:
  • 50 Day Moving Avg: $8.54
  • 200 Day Moving Avg: $7.87
  • 52 Week Range: $5.20 - $9.32
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 15.19
  • P/E Growth: 1.76
Sales & Book Value:
  • Annual Revenue: $47.7 million
  • Price / Sales: 3.87
  • Book Value: $5.98 per share
  • Price / Book: 1.35
Profitability:
  • EBIDTA: ($386,999.00)
  • Net Margins: 4.82%
  • Return on Equity: 1.95%
  • Return on Assets: 1.78%
Debt:
  • Current Ratio: 7.40%
  • Quick Ratio: 5.00%
Misc:
  • Average Volume: 12,026 shs.
  • Beta: 1.26
  • Short Ratio: 6.91
 

Frequently Asked Questions for Enzymotec Ltd (NASDAQ:ENZY)

What is Enzymotec Ltd's stock symbol?

Enzymotec Ltd trades on the NASDAQ under the ticker symbol "ENZY."

How were Enzymotec Ltd's earnings last quarter?

Enzymotec Ltd (NASDAQ:ENZY) posted its quarterly earnings data on Wednesday, May, 17th. The company reported $0.03 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.06 by $0.03. The firm had revenue of $12 million for the quarter, compared to analyst estimates of $14.23 million. Enzymotec Ltd had a return on equity of 1.95% and a net margin of 4.82%. The company's quarterly revenue was down 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.09 earnings per share. View Enzymotec Ltd's Earnings History.

Where is Enzymotec Ltd's stock going? Where will Enzymotec Ltd's stock price be in 2017?

2 equities research analysts have issued 12-month price targets for Enzymotec Ltd's stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Enzymotec Ltd's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Enzymotec Ltd.

What are analysts saying about Enzymotec Ltd stock?

Here are some recent quotes from research analysts about Enzymotec Ltd stock:

  • 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (5/22/2017)
  • 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)

Who are some of Enzymotec Ltd's key competitors?

Who owns Enzymotec Ltd stock?

Enzymotec Ltd's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Paulson & CO. Inc. (18.33%), Janus Capital Management LLC (1.26%), Renaissance Technologies LLC (1.26%), Acadian Asset Management LLC (1.03%), California Public Employees Retirement System (0.68%) and FMR LLC (0.37%). View Institutional Ownership Trends for Enzymotec Ltd.

Who sold Enzymotec Ltd stock? Who is selling Enzymotec Ltd stock?

Enzymotec Ltd's stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Menta Capital LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Enzymotec Ltd.

Who bought Enzymotec Ltd stock? Who is buying Enzymotec Ltd stock?

Enzymotec Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Geode Capital Management LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Enzymotec Ltd.

How do I buy Enzymotec Ltd stock?

Shares of Enzymotec Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Enzymotec Ltd stock cost?

One share of Enzymotec Ltd stock can currently be purchased for approximately $8.05.

Analyst Ratings

Consensus Ratings for Enzymotec Ltd (NASDAQ:ENZY) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (0.62% downside)

Analysts' Ratings History for Enzymotec Ltd (NASDAQ:ENZY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/23/2017Jefferies Group LLCReiterated RatingHold$8.00N/AView Rating Details
11/17/2016Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
4/17/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Enzymotec Ltd (NASDAQ:ENZY)
Earnings by Quarter for Enzymotec Ltd (NASDAQ:ENZY)
Earnings History by Quarter for Enzymotec Ltd (NASDAQ:ENZY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/17/20173/31/2017$0.06$0.03$14.23 million$12.00 millionViewN/AView Earnings Details
2/22/2017Q416$0.03($0.10)$11.47 million$10.60 millionViewN/AView Earnings Details
11/16/2016Q316$0.07$0.03$13.29 million$11.40 millionViewN/AView Earnings Details
8/9/2016Q216$0.08$0.04$14.90 million$15.00 millionViewN/AView Earnings Details
5/19/2016Q116$0.05$0.09$13.85 million$14.00 millionViewListenView Earnings Details
2/17/2016Q415$0.10$0.07$14.01 million$13.30 millionViewListenView Earnings Details
11/11/2015Q315$0.07$0.08$14.21 million$12.40 millionViewListenView Earnings Details
8/12/2015Q215$0.06$0.11$12.39 million$13.40 millionViewListenView Earnings Details
5/7/2015Q115$0.06$0.09$12.10 million$12.25 millionViewN/AView Earnings Details
2/18/2015Q414$0.08$0.06$11.11 million$10.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.04$0.05$10.22 million$9.50 millionViewN/AView Earnings Details
8/5/2014Q214$0.10$0.02$14.88 million$11.50 millionViewN/AView Earnings Details
5/14/2014Q114$0.17$0.24$19.40 million$23.70 millionViewN/AView Earnings Details
2/13/2014Q413$0.11$0.15$11.64 million$18.51 millionViewN/AView Earnings Details
11/11/2013Q313$0.11$0.13$13.10 million$22.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzymotec Ltd (NASDAQ:ENZY)
Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.53 EPS

Dividends

Dividend History for Enzymotec Ltd (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzymotec Ltd (NASDAQ:ENZY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Enzymotec Ltd (NASDAQ:ENZY)
Latest Headlines for Enzymotec Ltd (NASDAQ:ENZY)
Source:
DateHeadline
americanbankingnews.com logoEnzymotec Ltd (ENZY) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 22 at 7:34 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 20 at 12:32 AM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 19 at 9:46 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 19 at 2:26 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 18 at 8:12 AM
finance.yahoo.com logoInvestor Network: Enzymotec Ltd. to Host Earnings Call
finance.yahoo.com - May 17 at 10:56 AM
finance.yahoo.com logoEnzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results
finance.yahoo.com - May 17 at 10:56 AM
finance.yahoo.com logoEnzymotec misses 1Q profit forecasts
finance.yahoo.com - May 17 at 10:56 AM
americanbankingnews.com logoZacks: Enzymotec Ltd (ENZY) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 12 at 2:38 PM
americanbankingnews.com logoEnzymotec (ENZY) Getting Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 3 at 3:50 PM
finance.yahoo.com logoEnzymotec to Report First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 8:53 AM
finance.yahoo.com logoVAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods
finance.yahoo.com - May 2 at 7:27 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 28 at 10:36 PM
americanbankingnews.com logoEnzymotec (ENZY) Getting Somewhat Negative Press Coverage, Study Shows
www.americanbankingnews.com - April 21 at 12:49 PM
americanbankingnews.com logoEnzymotec (ENZY) Getting Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 17 at 9:03 PM
americanbankingnews.com logo Enzymotec Ltd (ENZY) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 13 at 6:28 PM
finance.yahoo.com logoENZYMOTEC LTD. Financials
finance.yahoo.com - March 22 at 5:11 PM
americanbankingnews.com logo Enzymotec Ltd (ENZY) Given Consensus Recommendation of "" by Brokerages
www.americanbankingnews.com - March 21 at 10:49 AM
finance.yahoo.com logoEnzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016
finance.yahoo.com - March 16 at 6:22 PM
feeds.benzinga.com logoEnzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders
feeds.benzinga.com - March 10 at 9:04 AM
finance.yahoo.com logoEnzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO
finance.yahoo.com - March 9 at 5:32 PM
finance.yahoo.com logo8:33 am Enzymotec appoints Erez Israeli as President and CEO effective April 18
finance.yahoo.com - March 9 at 5:32 PM
reuters.com logoBRIEF-Enzymotec Q4 non-GAAP loss per share $0.10
www.reuters.com - February 22 at 7:55 AM
finance.yahoo.com logoEnzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results
finance.yahoo.com - February 22 at 7:55 AM
finance.yahoo.com logoENZY : Summary for Enzymotec Ltd. - Yahoo Finance
finance.yahoo.com - February 13 at 10:51 PM
finance.yahoo.com logoEnzymotec Ltd. Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - February 6 at 9:43 AM
finance.yahoo.com logoCORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD …
finance.yahoo.com - January 25 at 3:47 AM
finance.yahoo.com logoPolyunsaturated Fatty Acids (PUFAs) Market: Rising Demand for Omega-3 and Omega-6 Fatty Acids Fuelling …
finance.yahoo.com - January 11 at 5:33 PM
finance.yahoo.com logoWhat Makes Enzymotec (ENZY) a Strong Sell?
finance.yahoo.com - December 12 at 11:52 AM
finance.yahoo.com logoEnzymotec downgraded by Wells Fargo
finance.yahoo.com - November 17 at 4:15 PM
baystreet.ca logoEnzymotec (ENZY) Off on Prospective Earnings
www.baystreet.ca - November 16 at 10:34 PM
finance.yahoo.com logoEdited Transcript of ENZY earnings conference call or presentation 16-Nov-16 1:30pm GMT
finance.yahoo.com - November 16 at 10:34 PM
globenewswire.com logoEnzymotec Ltd. Announces Departure of its CEO
globenewswire.com - November 16 at 8:01 AM
reuters.com logoBRIEF-Enzymotec Ltd. announces departure of its CEO
www.reuters.com - November 16 at 8:01 AM
finance.yahoo.com logoEnzymotec Ltd. Granted New Patents for INFAT® in the U.S., Vayacog® in Japan and Phospholipid-Based Products in Canada and Korea
finance.yahoo.com - September 27 at 9:25 AM

Social

Chart

Enzymotec Ltd (ENZY) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff